ProCE Banner Activity

LIBRETTO-531: Phase III Trial of Selpercatinib vs Cabozantinib or Vandetanib in Patients With Advanced RET-Mutant Medullary Thyroid Cancer

Conference Coverage

First-line selpercatinib improves PFS and time to treatment failure vs cabozantinib or vandetanib in an interim analysis of the phase III LIBRETTO-531 trial in patients with advanced RET-mutated medullary thyroid cancer.

Released: October 25, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.


Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.


Regeneron Pharmaceuticals, Inc